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ABSTRACT 
 As the cost of next-generation sequencing continues to decrease 
exponentially, it is becoming both affordable and relatively easy for laboratories 
outside of large-scale sequencing centers to perform exon capture and 
eventually whole genome sequencing in selected individuals. However, the 
current genomics system lacks a systematic way to deliver results to 
participants, even in matters of life and death, as we have discovered in some 
of our recent research1,2. There is substantial debate in the medical genetics 
and ethics communities concerning whether genomic data originating from 
research can or should be returned to participants or not, and, if so, under what 
conditions. The exponential increase in human genetic information is shining a 
spotlight on the problems with how researchers handle and process human 
genomic information. Specifically, researchers are largely unable to share the 
information that arises from their sequencing efforts with participants – without 
whom, the research wouldn’t be possible. At the moment, human genetics 
researchers operate in a totally unregulated environment, following their own 
protocols to obtain, store, track, and analyze DNA – creating many 
opportunities for samples to be mixed up, or other errors. Researchers take 
shortcuts to save time and money, given that most never expect (as did I) that 
their results might actually directly impact the unique life of another human 
being. Here, I present two real-world scenarios from our own research 
highlighting the issues involved1,2. I am suggesting that we change the way we 
collect and process samples for human genetics research. I argue that we 
should create a formalized protocol akin to the rigorous process doctors and 
other healthcare workers go through during any clinical lab test, practically 
eliminating the chances of mistakes and mix-ups. An added benefit is that 
sharing the genomic data with research participants will allow them the 
opportunity to share their own data with other researchers and citizen-
scientists, thus allowing for potentially faster and easier replication of published 
results. We cannot forget the wise words of the late Charles Epstein, from his 
2001 William Allan award lecture: “the operative word in ‘human genetics’ is 
‘human.’ Human genetics is about human beings—about humanity and 
humaneness.”3  
RESULTS 
Last year, we characterized a unique, previously unrecognized syndrome, with 
an X-linked inheritance pattern in two unrelated families (Table 1 and Figure 1 
and 2)1. We used X-chromosome exon capture and sequencing to determine 
variants that might be responsible for the disorder. We then used a new 
probabilistic disease-gene discovery algorithm (VAAST) to determine the 
genetic basis of this illness. This variant was absent in ~6000 other exomes, 
and we performed biological studies to further bolster proof of causality1. We 
suggested calling this disease Ogden syndrome, in honor of the town in which 
the family lives. Last year, we also performed exome sequencing on another 
family and discovered an unrelated, secondary finding explaining the genetic 
basis of idiopathic hemolytic anemia in one family member (Figure 3) 2,5. 
 However, in both of these studies, this research was not conducted in a 
CLIA-certified laboratory, nor was the blood collected or processed in a clinical-
grade manner. All Clinical Diagnostic Tests are regulated in America within 
Clinical Laboratory Improvement Amendments (CLIA)-certified laboratories, and 
preferably also with College of American Pathology (CAP) certification. 
Delivering research-grade results back to research participants can lead to 
errors and confusion. Prior to the implementation of CLIA, several women were 
given false negative Pap smear results derived from faulty laboratory testing. 
These women subsequently developed cervical cancer and died. There have 
been other instances of faulty test results with breast cancer (BRCA-1) and HIV. 
The Hippocratic Oath includes the statement, “First, do no harm”. From a 
physician perspective, this means that all laboratory testing should achieve a 
high standard of analytic validity. 
 Once a laboratory test meets this standard of high analytic validity, the next 
question is whether there is clinical validity (or utility) for this accurate test 
result. Unfortunately, much human genetic variation is currently locked away in 
various databases and siloes, not available broadly. There is therefore an 
enormous need for one broad database of human genotype-phenotype 
correlations, so that penetrance (or expressivity) of individual rare mutations 
can be best calculated. Otherwise, it is very difficult to calculate the penetrance 
of any one mutation. It is also incredibly important to calculate penetrance 
within “clans”, so as to avoid confounding factors such as population 
stratification and environmental effects.  
 
 
 
CONCLUSIONS 
Why not help the families and research participants directly now by 
deriving maximal value from every human we sequence? This could be 
enabled by engagement with social media (e.g. Facebook) and 
consumer-driven genomics (e.g. PatientsLikeMe and 23andMe). 
The entire process of DNA collection and germline genome 
sequencing for humans could and should be performed from the outset 
in a proper clinical environment, so that at least physicians and genetic 
counselors can immediately return all relevant genomic information 
much more easily, and perhaps even link such information to medical 
records, so that it is available for re-analysis as our knowledge 
expands.  
To make these changes possible, we must establish new clinically 
certified protocols for obtaining, processing, cataloging and returning 
human genomic data, including genetic findings perhaps unrelated (or 
secondary) to the original research goals2,5.  
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Table 1. Features of the syndrome 
Growth post-natal growth failure 
Development global, severe delays 
Facial prominence of eyes, down-sloping palpebral 
fissures, thickened lids 
large ears 
beaking of nose, flared nares, hypoplastic alae, 
short columella 
protruding upper lip 
micro-retrognathia 
Skeletal delayed closure of fontanels 
broad great toes 
Integument redundancy / laxity of skin 
minimal subcutaneous fat 
cutaneous capillary malformations 
persistent lanugo of the face 
Cardiac ventricular septal and atrial level defects, pulmonary 
artery stenoses) 
arrhythmias (Torsade de points, PVCs, PACs, SVtach, 
Vtach) 
death usually associated with cardiogenic shock 
preceded by arrythmia. 
Genital inguinal hernia 
hypo- or cryptorchidism 
Neurologic hypotonia progressing to hypertonia 
cerebral atrophy 
neurogenic scoliosis  
The shaded region includes features of the syndrome demonstrating 
variability. Though variable findings of the cardiac, genital and neurologic 
systems were observed, all affected individuals manifested some pathologic 
finding of each. 
	
Figure 1. 
Figure 1. Pedigree drawing and Pictures of Families 1 and 2. A) Pedigree drawing for Family 1. 
The most recent deceased III-4 is indicated by an arrow. SB, stillborn. Genotypes are marked for 
those in which DNA was available and tested. + is normal variant, mt is rare mutant variant. B) 
Pictures of four affected/deceased boys in this family, showing the aged appearance. C) Sanger 
sequencing results of NAA10 in III-4 from Family 1. D) Pedigree for Family 2 contributed by Les 
Biesecker at NIH. The most recent deceased III-2 is indicated by an arrow. E) Picture of II-I and III-2 
at ~1 year of age in Family 2. 
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Figure 2. Triptych of III-4 from Family 1.  These pictures demonstrate 
the prominence of eyes, down-sloping palpebral fissures, thickened lids, 
large ears, beaking of nose, flared nares, hypoplastic alae, short 
columella, protruding upper lip and micro-retrognathia.  
Figure 3. 
 
Figure 3. The pedigree structure is shown, with 
corresponding ID numbers. The three subjects in the pedigree 
affected with ADHD are shaded. Only 84060 has the idiopathic 
hemolytic anemia. The mother, father and two sons were 
sequenced. The two sisters in the family declined to participate 
in the study, thus their phenotype status is unknown and marked 
as “?”. 
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Figure 4. Genome browser shot of PKLR and the location of the 
two causal mutations for the hemolytic anemia. Each of the two 
mutations sits within an evolutionarily conserved region, and has been 
reported once in patients affected with PKLR deficiency.  
 We are in the midst of a profound social revolution 
with the advent of digital technologies and companies 
and foundations such as Google, Amazon, Facebook, 
Twitter, 23andMe, PatientsLikeMe, Ancestry.com, and 
Sage Bionetworks. It is my opinion that centralized 
whole genome sequencing with high analytic validity 
could allow for deposition of whole genome data in a 
central repository of Human Genotype-Phenotype 
correlations. However, such a central database has not 
yet been fully created. 
 
 
 
 
 
